HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.

AbstractBACKGROUND:
Understanding how tumor response is related to relapse risk would help clinicians make decisions about additional treatment options for patients who have received neoadjuvant endocrine treatment for estrogen receptor-positive (ER+) breast cancer.
METHODS:
Tumors from 228 postmenopausal women with confirmed ER+ stage 2 and 3 breast cancers in the P024 neoadjuvant endocrine therapy trial, which compared letrozole and tamoxifen for 4 months before surgery, were analyzed for posttreatment ER status, Ki67 proliferation index, histological grade, pathological tumor size, node status, and treatment response. Cox proportional hazards were used to identify factors associated with relapse-free survival (RFS) and breast cancer-specific survival (BCSS) in 158 women. A preoperative endocrine prognostic index (PEPI) for RFS was developed from these data and validated in an independent study of 203 postmenopausal women in the IMPACT trial, which compared treatment with anastrozole, tamoxifen, or the combination 3 months before surgery. Statistical tests were two-sided.
RESULTS:
Median follow-up in P024 was 61.2 months. Patients with confirmed baseline ER+ clinical stage 2 and 3 tumors that were downstaged to stage 1 or 0 at surgery had 100% RFS (compared with higher stages, P < .001). Multivariable testing of posttreatment tumor characteristics revealed that pathological tumor size, node status, Ki67 level, and ER status were independently associated with both RFS and BCSS. The PEPI model based on these factors predicted RFS in the IMPACT trial (P = .002).
CONCLUSIONS:
Breast cancer patients with pathological stage 1 or 0 disease after neoadjuvant endocrine therapy and a low-risk biomarker profile in the surgical specimen (PEPI score 0) have an extremely low risk of relapse and are therefore unlikely to benefit from adjuvant chemotherapy.
AuthorsMatthew J Ellis, Yu Tao, Jingqin Luo, Roger A'Hern, Dean B Evans, Ajay S Bhatnagar, Hilary A Chaudri Ross, Alexander von Kameke, William R Miller, Ian Smith, Wolfgang Eiermann, Mitch Dowsett
JournalJournal of the National Cancer Institute (J Natl Cancer Inst) Vol. 100 Issue 19 Pg. 1380-8 (Oct 1 2008) ISSN: 1460-2105 [Electronic] United States
PMID18812550 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Antineoplastic Agents, Hormonal
  • Aromatase Inhibitors
  • Biomarkers, Tumor
  • Ki-67 Antigen
  • Nitriles
  • Receptors, Estrogen
  • Triazoles
  • Tamoxifen
  • anastrozole
  • letrozole
Topics
  • Aged
  • Analysis of Variance
  • Antineoplastic Agents, Hormonal (therapeutic use)
  • Aromatase Inhibitors (therapeutic use)
  • Biomarkers, Tumor (analysis)
  • Breast Neoplasms (chemistry, drug therapy, pathology, surgery)
  • Chemotherapy, Adjuvant
  • Clinical Trials as Topic
  • Disease-Free Survival
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Ki-67 Antigen (analysis)
  • Lymphatic Metastasis
  • Middle Aged
  • Neoadjuvant Therapy (methods)
  • Neoplasm Staging
  • Nitriles (therapeutic use)
  • Postmenopause
  • Predictive Value of Tests
  • Prognosis
  • Proportional Hazards Models
  • Receptors, Estrogen (analysis)
  • Reproducibility of Results
  • Risk Assessment
  • Risk Factors
  • Tamoxifen (therapeutic use)
  • Treatment Outcome
  • Triazoles (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: